Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nanoparticles | 23 | 2022 | 254 | 3.340 |
Why?
|
Polyesters | 6 | 2021 | 55 | 2.020 |
Why?
|
Drug Delivery Systems | 10 | 2021 | 236 | 1.530 |
Why?
|
Nanotechnology | 4 | 2021 | 109 | 1.400 |
Why?
|
Nanostructures | 6 | 2021 | 112 | 1.370 |
Why?
|
Drug Carriers | 8 | 2021 | 90 | 1.120 |
Why?
|
Metal Nanoparticles | 2 | 2020 | 88 | 1.060 |
Why?
|
Biocompatible Materials | 3 | 2021 | 247 | 0.990 |
Why?
|
Nanomedicine | 3 | 2014 | 19 | 0.980 |
Why?
|
Polymers | 9 | 2020 | 244 | 0.960 |
Why?
|
Spheroids, Cellular | 2 | 2013 | 45 | 0.940 |
Why?
|
Eupatorium | 1 | 2023 | 1 | 0.920 |
Why?
|
Arthropods | 1 | 2022 | 8 | 0.870 |
Why?
|
Penaeidae | 1 | 2022 | 16 | 0.870 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 1070 | 0.850 |
Why?
|
Biodiversity | 1 | 2021 | 16 | 0.830 |
Why?
|
Plant Extracts | 1 | 2023 | 122 | 0.830 |
Why?
|
Tissue Engineering | 2 | 2013 | 212 | 0.830 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 92 | 0.820 |
Why?
|
Anti-Infective Agents | 1 | 2022 | 166 | 0.780 |
Why?
|
Cross Infection | 1 | 2022 | 195 | 0.770 |
Why?
|
Paclitaxel | 2 | 2014 | 140 | 0.710 |
Why?
|
Lactic Acid | 3 | 2015 | 86 | 0.710 |
Why?
|
Gold | 1 | 2020 | 76 | 0.710 |
Why?
|
Sirolimus | 2 | 2014 | 118 | 0.700 |
Why?
|
Betacoronavirus | 1 | 2020 | 116 | 0.690 |
Why?
|
Environmental Restoration and Remediation | 1 | 2018 | 18 | 0.660 |
Why?
|
Optical Imaging | 1 | 2018 | 46 | 0.650 |
Why?
|
Coronavirus Infections | 1 | 2020 | 143 | 0.620 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 154 | 0.610 |
Why?
|
Magnetic Phenomena | 2 | 2013 | 12 | 0.600 |
Why?
|
Magnetite Nanoparticles | 2 | 2013 | 28 | 0.590 |
Why?
|
Biomedical Research | 1 | 2020 | 310 | 0.590 |
Why?
|
Pandemics | 1 | 2020 | 346 | 0.580 |
Why?
|
Diagnostic Imaging | 2 | 2015 | 201 | 0.560 |
Why?
|
Contrast Media | 4 | 2022 | 594 | 0.540 |
Why?
|
Animals | 22 | 2022 | 20877 | 0.530 |
Why?
|
Neoplasms | 5 | 2020 | 1660 | 0.530 |
Why?
|
Iodine | 1 | 2015 | 41 | 0.510 |
Why?
|
Cell Survival | 6 | 2021 | 901 | 0.500 |
Why?
|
Polyglycolic Acid | 1 | 2013 | 20 | 0.480 |
Why?
|
Molecular Imaging | 1 | 2014 | 45 | 0.470 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 118 | 0.460 |
Why?
|
Thiazoles | 1 | 2013 | 95 | 0.460 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 222 | 0.460 |
Why?
|
Nanotubes, Carbon | 1 | 2013 | 73 | 0.450 |
Why?
|
Aorta | 2 | 2013 | 316 | 0.450 |
Why?
|
Pyrimidines | 1 | 2013 | 178 | 0.430 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 144 | 0.430 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 331 | 0.420 |
Why?
|
Magnetic Fields | 1 | 2011 | 21 | 0.400 |
Why?
|
Cell Proliferation | 3 | 2019 | 1173 | 0.390 |
Why?
|
Glioblastoma | 1 | 2013 | 219 | 0.390 |
Why?
|
Hyperthermia, Induced | 1 | 2011 | 53 | 0.380 |
Why?
|
Humans | 28 | 2022 | 68525 | 0.350 |
Why?
|
Pharmaceutical Preparations | 3 | 2021 | 100 | 0.330 |
Why?
|
Microscopy, Electron, Transmission | 3 | 2020 | 127 | 0.330 |
Why?
|
Urologic Neoplasms | 1 | 2008 | 14 | 0.320 |
Why?
|
Receptor, ErbB-2 | 1 | 2008 | 128 | 0.320 |
Why?
|
Graphite | 2 | 2021 | 46 | 0.300 |
Why?
|
ErbB Receptors | 1 | 2008 | 239 | 0.300 |
Why?
|
Environmental Pollutants | 2 | 2021 | 180 | 0.290 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 510 | 0.270 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 1026 | 0.270 |
Why?
|
Aptamers, Nucleotide | 3 | 2012 | 15 | 0.270 |
Why?
|
X-Rays | 4 | 2022 | 56 | 0.260 |
Why?
|
Cell Line, Tumor | 6 | 2021 | 1849 | 0.240 |
Why?
|
Rats | 5 | 2019 | 5300 | 0.240 |
Why?
|
X-Ray Diffraction | 2 | 2021 | 53 | 0.230 |
Why?
|
Plant Leaves | 1 | 2023 | 49 | 0.220 |
Why?
|
Luminescence | 2 | 2013 | 31 | 0.220 |
Why?
|
Nanocapsules | 2 | 2013 | 10 | 0.220 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2022 | 21 | 0.220 |
Why?
|
Hydrogels | 1 | 2023 | 54 | 0.220 |
Why?
|
Calcium Fluoride | 1 | 2021 | 2 | 0.210 |
Why?
|
Malaria | 1 | 2021 | 26 | 0.200 |
Why?
|
Microscopy, Confocal | 2 | 2020 | 337 | 0.200 |
Why?
|
Pesticides | 1 | 2021 | 41 | 0.200 |
Why?
|
Stents | 2 | 2013 | 657 | 0.200 |
Why?
|
Gold Radioisotopes | 1 | 2020 | 1 | 0.200 |
Why?
|
Photosensitizing Agents | 1 | 2021 | 32 | 0.200 |
Why?
|
Organosilicon Compounds | 1 | 2020 | 5 | 0.200 |
Why?
|
Radioisotopes | 1 | 2020 | 40 | 0.190 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2021 | 57 | 0.190 |
Why?
|
Microscopy, Fluorescence | 2 | 2020 | 261 | 0.190 |
Why?
|
Antioxidants | 1 | 2023 | 304 | 0.190 |
Why?
|
Ultrasonography | 2 | 2022 | 453 | 0.190 |
Why?
|
Dynamic Light Scattering | 1 | 2020 | 3 | 0.190 |
Why?
|
Mice | 7 | 2022 | 8472 | 0.190 |
Why?
|
Propane | 1 | 2020 | 5 | 0.190 |
Why?
|
Intensive Care Units | 1 | 2022 | 344 | 0.190 |
Why?
|
Polyethylene Glycols | 2 | 2013 | 149 | 0.190 |
Why?
|
RAW 264.7 Cells | 1 | 2020 | 42 | 0.190 |
Why?
|
Amino Acid Sequence | 1 | 2022 | 1082 | 0.190 |
Why?
|
3T3 Cells | 1 | 2020 | 124 | 0.180 |
Why?
|
Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 72 | 0.180 |
Why?
|
Chromogenic Compounds | 1 | 2019 | 3 | 0.180 |
Why?
|
Photochemical Processes | 1 | 2019 | 10 | 0.180 |
Why?
|
Tumor Cells, Cultured | 2 | 2013 | 852 | 0.180 |
Why?
|
Nanofibers | 1 | 2019 | 21 | 0.180 |
Why?
|
Ultraviolet Rays | 1 | 2020 | 130 | 0.180 |
Why?
|
Tissue Distribution | 3 | 2021 | 282 | 0.180 |
Why?
|
Drug Design | 3 | 2008 | 107 | 0.170 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2020 | 120 | 0.170 |
Why?
|
Metals | 1 | 2019 | 100 | 0.170 |
Why?
|
Alveolar Bone Loss | 1 | 2019 | 40 | 0.170 |
Why?
|
Disease Management | 1 | 2020 | 248 | 0.170 |
Why?
|
Periodontitis | 1 | 2019 | 47 | 0.170 |
Why?
|
Kaolin | 1 | 2018 | 23 | 0.170 |
Why?
|
Volatile Organic Compounds | 1 | 2018 | 14 | 0.170 |
Why?
|
Magnetic Resonance Imaging | 3 | 2018 | 2222 | 0.160 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 155 | 0.160 |
Why?
|
Environmental Monitoring | 1 | 2019 | 180 | 0.160 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 234 | 0.160 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 160 | 0.150 |
Why?
|
Melanoma | 1 | 2021 | 335 | 0.150 |
Why?
|
Delivery of Health Care | 1 | 2021 | 445 | 0.150 |
Why?
|
Skin Neoplasms | 1 | 2021 | 375 | 0.140 |
Why?
|
Intestinal Mucosa | 2 | 2015 | 219 | 0.140 |
Why?
|
Carboxylic Acids | 1 | 2015 | 24 | 0.140 |
Why?
|
Aldehydes | 1 | 2015 | 34 | 0.140 |
Why?
|
Polyethyleneimine | 1 | 2015 | 14 | 0.140 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2014 | 618 | 0.130 |
Why?
|
Biological Availability | 2 | 2015 | 79 | 0.130 |
Why?
|
Prostatic Neoplasms | 3 | 2012 | 778 | 0.130 |
Why?
|
Ferrosoferric Oxide | 2 | 2019 | 10 | 0.130 |
Why?
|
Molecular Weight | 1 | 2015 | 358 | 0.130 |
Why?
|
Carbon | 1 | 2015 | 122 | 0.120 |
Why?
|
Rabbits | 1 | 2015 | 509 | 0.120 |
Why?
|
Drug Liberation | 1 | 2014 | 17 | 0.120 |
Why?
|
Vaccines, Synthetic | 1 | 2014 | 19 | 0.120 |
Why?
|
Lipids | 2 | 2022 | 298 | 0.120 |
Why?
|
Polymerization | 1 | 2013 | 17 | 0.120 |
Why?
|
Apoferritins | 1 | 2013 | 6 | 0.120 |
Why?
|
Receptors, Fc | 1 | 2013 | 19 | 0.120 |
Why?
|
Dasatinib | 1 | 2013 | 17 | 0.120 |
Why?
|
Horses | 1 | 2013 | 20 | 0.120 |
Why?
|
Adjuvants, Immunologic | 1 | 2014 | 63 | 0.120 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2013 | 24 | 0.120 |
Why?
|
Oxides | 1 | 2013 | 47 | 0.120 |
Why?
|
Optical Phenomena | 1 | 2013 | 5 | 0.110 |
Why?
|
Fibroblasts | 2 | 2019 | 902 | 0.110 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 195 | 0.110 |
Why?
|
Cattle | 1 | 2013 | 475 | 0.110 |
Why?
|
Kinetics | 1 | 2013 | 1047 | 0.110 |
Why?
|
Stem Cells | 1 | 2013 | 248 | 0.100 |
Why?
|
Prostheses and Implants | 1 | 2013 | 159 | 0.100 |
Why?
|
MCF-7 Cells | 3 | 2019 | 80 | 0.100 |
Why?
|
Iron | 1 | 2013 | 197 | 0.100 |
Why?
|
Chemical Phenomena | 1 | 2011 | 62 | 0.100 |
Why?
|
Cells, Cultured | 2 | 2014 | 2673 | 0.100 |
Why?
|
Particle Size | 2 | 2008 | 201 | 0.100 |
Why?
|
Silicon Dioxide | 2 | 2022 | 61 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 1 | 2013 | 331 | 0.100 |
Why?
|
Surface Properties | 2 | 2008 | 363 | 0.090 |
Why?
|
Liposomes | 1 | 2010 | 107 | 0.090 |
Why?
|
Administration, Oral | 3 | 2015 | 411 | 0.090 |
Why?
|
Maleimides | 1 | 2008 | 15 | 0.090 |
Why?
|
Neoplasm Metastasis | 1 | 2010 | 306 | 0.080 |
Why?
|
Micelles | 1 | 2008 | 43 | 0.080 |
Why?
|
Magnetics | 1 | 2008 | 52 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 2323 | 0.080 |
Why?
|
Dendrimers | 1 | 2008 | 12 | 0.080 |
Why?
|
Crystallization | 2 | 2021 | 57 | 0.070 |
Why?
|
Male | 6 | 2021 | 37281 | 0.060 |
Why?
|
Endothelial Cells | 2 | 2021 | 384 | 0.060 |
Why?
|
Structure-Activity Relationship | 2 | 2020 | 420 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2008 | 848 | 0.060 |
Why?
|
Food Chain | 1 | 2021 | 11 | 0.050 |
Why?
|
Primaquine | 1 | 2021 | 12 | 0.050 |
Why?
|
Soil | 1 | 2021 | 51 | 0.050 |
Why?
|
Plasmodium falciparum | 1 | 2021 | 45 | 0.050 |
Why?
|
Polyvinyl Alcohol | 1 | 2021 | 8 | 0.050 |
Why?
|
Isoindoles | 1 | 2021 | 9 | 0.050 |
Why?
|
Zinc Compounds | 1 | 2021 | 9 | 0.050 |
Why?
|
Dacarbazine | 1 | 2021 | 32 | 0.050 |
Why?
|
Polytetrafluoroethylene | 1 | 2021 | 55 | 0.050 |
Why?
|
Drug Compounding | 1 | 2021 | 34 | 0.050 |
Why?
|
Photochemotherapy | 1 | 2021 | 59 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2020 | 2790 | 0.050 |
Why?
|
Zymosan | 1 | 2020 | 12 | 0.050 |
Why?
|
Time Factors | 1 | 2008 | 4655 | 0.050 |
Why?
|
Organometallic Compounds | 1 | 2021 | 95 | 0.050 |
Why?
|
HT29 Cells | 1 | 2019 | 42 | 0.050 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2019 | 45 | 0.050 |
Why?
|
Doxorubicin | 1 | 2020 | 231 | 0.040 |
Why?
|
Aggregatibacter actinomycetemcomitans | 1 | 2019 | 18 | 0.040 |
Why?
|
X-Ray Microtomography | 1 | 2019 | 50 | 0.040 |
Why?
|
Female | 3 | 2021 | 38015 | 0.040 |
Why?
|
Cell Cycle | 1 | 2019 | 312 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 1745 | 0.030 |
Why?
|
Liver | 1 | 2021 | 1118 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2015 | 62 | 0.030 |
Why?
|
Toll-Like Receptor 8 | 1 | 2014 | 3 | 0.030 |
Why?
|
Toll-Like Receptor 9 | 1 | 2014 | 12 | 0.030 |
Why?
|
Spectrophotometry, Ultraviolet | 1 | 2014 | 79 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2014 | 35 | 0.030 |
Why?
|
Toll-Like Receptor 7 | 1 | 2014 | 17 | 0.030 |
Why?
|
Antigens | 1 | 2014 | 90 | 0.030 |
Why?
|
Spectrometry, Fluorescence | 1 | 2014 | 112 | 0.030 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2014 | 236 | 0.030 |
Why?
|
Antibody Formation | 1 | 2014 | 93 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2014 | 80 | 0.030 |
Why?
|
Terbium | 1 | 2013 | 5 | 0.030 |
Why?
|
Spleen | 1 | 2014 | 301 | 0.030 |
Why?
|
Imidazoles | 1 | 2014 | 175 | 0.030 |
Why?
|
Spectrum Analysis, Raman | 1 | 2013 | 38 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2015 | 269 | 0.030 |
Why?
|
Europium | 1 | 2013 | 8 | 0.030 |
Why?
|
Chickens | 1 | 2014 | 232 | 0.030 |
Why?
|
Photons | 1 | 2013 | 32 | 0.030 |
Why?
|
Fibrinogen | 1 | 2013 | 87 | 0.030 |
Why?
|
Serum Albumin | 1 | 2013 | 104 | 0.030 |
Why?
|
Biological Transport | 1 | 2013 | 210 | 0.030 |
Why?
|
Alloys | 1 | 2013 | 66 | 0.030 |
Why?
|
Gadolinium | 1 | 2013 | 88 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2020 | 2550 | 0.030 |
Why?
|
Adsorption | 1 | 2013 | 225 | 0.030 |
Why?
|
Insulin | 1 | 2015 | 617 | 0.030 |
Why?
|
Actins | 1 | 2013 | 249 | 0.030 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2013 | 317 | 0.020 |
Why?
|
Blotting, Western | 1 | 2013 | 954 | 0.020 |
Why?
|
Genetic Therapy | 1 | 2012 | 291 | 0.020 |
Why?
|
Cytokines | 1 | 2014 | 866 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2013 | 1692 | 0.020 |
Why?
|
Macromolecular Substances | 1 | 2008 | 122 | 0.020 |
Why?
|
Solubility | 1 | 2008 | 134 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2008 | 111 | 0.020 |
Why?
|
Diffusion | 1 | 2008 | 90 | 0.020 |
Why?
|
Molecular Conformation | 1 | 2008 | 128 | 0.020 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2008 | 85 | 0.020 |
Why?
|
Materials Testing | 1 | 2008 | 263 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2007 | 381 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2007 | 475 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2012 | 7028 | 0.010 |
Why?
|